Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.

IF 7.4 1区 医学 Q1 HEMATOLOGY
Kai Zhao, Jieqing Zhu, Sarah Rosenberger, Meng Zhou, Warren D Shlomchik
{"title":"Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.","authors":"Kai Zhao, Jieqing Zhu, Sarah Rosenberger, Meng Zhou, Warren D Shlomchik","doi":"10.1182/bloodadvances.2024013291","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>In allogeneic hematopoietic stem cell transplantation (allo-SCT), alloreactive donor T cells mediate the graft-versus-leukemia effect but also attack nonhematopoietic tissues, causing graft-versus-host disease (GVHD). Reducing alloreactive T-cell trafficking to GVHD target tissues while allowing their access to bone marrow (BM) and spleen, major sites of malignant hematopoiesis, is a rational strategy for reducing the GVHD risk when using alloreactive T cells as a therapeutic. Here, we show that effector T-cell (Teff) entry into BM and spleen in unmanipulated mice and in mice that received transplantation without alloreactive T cells is augmented by pertussis toxin (PTX)-sensitive chemokine receptor signaling. However, unexpectedly, in the presence of a GVH response, chemokines no longer draw T cells into BM and spleen but remain critical for their recruitment to GVHD target tissues. Consistent with this, PTX-treated Teff cells were as efficacious as untreated T cells in killing leukemia cells in BM and spleen in mice with a concurrent GVHD response. These results suggest a strategy to improve the safety of alloreactive T-cell therapeutics in treating leukemias in the context of an allo-SCT.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"209-221"},"PeriodicalIF":7.4000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788131/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024013291","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: In allogeneic hematopoietic stem cell transplantation (allo-SCT), alloreactive donor T cells mediate the graft-versus-leukemia effect but also attack nonhematopoietic tissues, causing graft-versus-host disease (GVHD). Reducing alloreactive T-cell trafficking to GVHD target tissues while allowing their access to bone marrow (BM) and spleen, major sites of malignant hematopoiesis, is a rational strategy for reducing the GVHD risk when using alloreactive T cells as a therapeutic. Here, we show that effector T-cell (Teff) entry into BM and spleen in unmanipulated mice and in mice that received transplantation without alloreactive T cells is augmented by pertussis toxin (PTX)-sensitive chemokine receptor signaling. However, unexpectedly, in the presence of a GVH response, chemokines no longer draw T cells into BM and spleen but remain critical for their recruitment to GVHD target tissues. Consistent with this, PTX-treated Teff cells were as efficacious as untreated T cells in killing leukemia cells in BM and spleen in mice with a concurrent GVHD response. These results suggest a strategy to improve the safety of alloreactive T-cell therapeutics in treating leukemias in the context of an allo-SCT.

效应 T 细胞迁移到 GVHD 组织需要趋化因子受体,而迁移到骨髓则不需要趋化因子受体。
在异体造血干细胞移植(alloSCT)中,异体活性供体T细胞介导移植物抗白血病(GVL)效应,但也会攻击非造血组织,导致移植物抗宿主疾病(GVHD)。减少异体活性 T 细胞向 GVHD 靶组织的贩运,同时允许它们进入骨髓(BM)和脾脏(恶性造血的主要部位),是使用异体活性 T 细胞作为疗法时降低 GVHD 风险的合理策略。在这里,我们发现,百日咳毒素敏感性趋化因子受体(PTX)信号传导会促进效应T细胞(Teff)进入未受操纵的小鼠和无异体活性T细胞移植的小鼠的骨髓和脾脏。然而,出乎意料的是,在出现 GVHD 反应时,趋化因子不再吸引 T 细胞进入 BM 和脾脏,但仍对它们招募到 GVHD 靶组织至关重要。与此相一致的是,经 PTX 处理的 Teff 细胞与未经处理的 T 细胞一样,能有效杀死同时出现 GVHD 反应的小鼠 BM 和脾脏中的白血病细胞。这些结果为提高异体活性 T 细胞疗法在异体 SCT 治疗白血病时的安全性提供了一种策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信